For CIDP, evidence is also emerging that patients previously maintained on IVIg treatment may undergo disease worsening upon switching to FcRn antagonists, underlining the fact that other disease drivers than solely auto-Abs are also vital aspects of pathophysiology in at least certain patients with CIDP [265, 401, 402]
Starting at a low initial dose gives the gut time to adjust to these changes gradually
To lessen discomfort, we keep a careful eye on you and modify your dosage as necessary
Medical protocols prioritize safety and metabolic stability over aggressive dosing strategies
The side effect profile remains comparable between genders, though women reported slightly higher nausea rates at 31% compared to 24% for men
Increases Sexual Desire in Premenopausal Women With Acquired HSDD PT-141s top benefit and the basis for its FDA approval is that it increases sexual desire in premenopausal women with acquired HSDD